Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DE:4DN)
FRANKFURT:4DN
4DN Stock Chart & Stats
€15.90
€2.53(14.09%)
At close: 4:00 PM EST
€15.90
€2.53(14.09%)
Day’s Range― - ―
52-Week Range€10.17 - €23.46
Previous CloseN/A
Volume0.00
Average Volume (3M)293.00
Market Cap
$1.90B
Enterprise Value€1.55B
Total Cash (Recent Filing)$848.20M
Total Debt (Recent Filing)$44.40M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Mar 02, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding146,212,280
10 Day Avg. Volume139
30 Day Avg. Volume293
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.73
Price to Sales (P/S)0.00
P/FCF Ratio-9.22
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.73
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$26.64Price Target Upside67.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth StrategyDenali announced its D3 strategy to discover, develop, and deliver on its TV platform, indicating a clear plan for future growth.
Pipeline ExpansionThe company continues to execute on expanding its clinical pipeline, achieving its target of bringing two preclinical assets forward in 2025, with an additional one to two targeted annually moving forward.
Regulatory DevelopmentsDenali Therapeutics is experiencing positive regulatory developments that support its lead program, tividenofusp alfa, which has the potential to become a commercially disruptive program for Hunter's disease patients.
Bears Say
Clinical Program SetbacksThere have been some setbacks with a priority review voucher now not expected or included in financial guidance if tivi is approved and the Pompe clinical programs being placed on FDA clinical hold.
Leadership ChangesThe departure of Chief Medical Officer Carole Ho may be seen as a negative factor, although Dr. Peter Chin has been named Acting CMO and Head of Development.
Regulatory DelaysThe recent delay in the 310 regulatory process resulted in a new PDUFA date of April 5th.
Denali Therapeutics News
4DN FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was €10.17 and its highest was €23.46 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $1.90B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 84 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Nov 06, 2025. The company reported -€0.638 earnings per share for the quarter, beating the consensus estimate of -€0.645 by €0.007.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.64.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 146,212,280 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -€0.638 in its last earnings report, beating expectations of -€0.645. Following the earnings report the stock price went down -3.158%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DE:4DN
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.64 (67.54% Upside)
$26.64 (67.54% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.47%
12-Months-Change
Fundamentals
Return on Equity
-39.69%
Trailing 12-Months
Asset Growth
-22.38%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
4DN Stock 12 Month Forecast
Average Price Target
€26.64
▲(67.54% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Options Prices
Currently, No data available
---